Equities Analysts Offer Predictions for Turning Point Therapeutics’ Q1 2019 Earnings (TPTX)

Share on StockTwits

Turning Point Therapeutics (NASDAQ:TPTX) – Stock analysts at Svb Leerink issued their Q1 2019 EPS estimates for Turning Point Therapeutics in a research report issued to clients and investors on Monday, May 13th. Svb Leerink analyst A. Berens expects that the company will earn ($0.69) per share for the quarter. Svb Leerink currently has a “Outperform” rating and a $42.00 target price on the stock. Svb Leerink also issued estimates for Turning Point Therapeutics’ Q2 2019 earnings at ($0.45) EPS, Q3 2019 earnings at ($0.60) EPS, Q4 2019 earnings at ($0.74) EPS, FY2019 earnings at ($2.44) EPS, FY2020 earnings at ($3.54) EPS, FY2021 earnings at ($4.64) EPS, FY2022 earnings at ($3.43) EPS and FY2023 earnings at ($0.33) EPS.

TPTX has been the subject of a number of other research reports. Canaccord Genuity assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set a “buy” rating and a $48.00 target price for the company. Wells Fargo & Co assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set an “outperform” rating and a $53.00 target price for the company. Goldman Sachs Group assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set a “buy” rating and a $50.00 target price for the company. Royal Bank of Canada assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set an “outperform” rating and a $48.00 target price for the company. Finally, Leerink Swann assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set an “outperform” rating and a $42.00 target price for the company. Six analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $47.17.

Shares of NASDAQ:TPTX opened at $34.27 on Thursday. Turning Point Therapeutics has a 12-month low of $24.21 and a 12-month high of $38.00.

In other Turning Point Therapeutics news, major shareholder Cormorant Asset Management, Lp acquired 400,000 shares of Turning Point Therapeutics stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average price of $18.00 per share, with a total value of $7,200,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Athena Countouriotis acquired 12,000 shares of Turning Point Therapeutics stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average cost of $18.00 per share, with a total value of $216,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 774,800 shares of company stock valued at $13,946,400.

About Turning Point Therapeutics

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Further Reading: What is a Lock-Up Period?

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

American Homes 4 Rent  CEO David P. Singelyn Sells 35,535 Shares
American Homes 4 Rent CEO David P. Singelyn Sells 35,535 Shares
First Republic Investment Management Inc. Purchases New Holdings in Blackbaud, Inc.
First Republic Investment Management Inc. Purchases New Holdings in Blackbaud, Inc.
Edgewell Personal Care Co  Shares Sold by First Republic Investment Management Inc.
Edgewell Personal Care Co Shares Sold by First Republic Investment Management Inc.
Coastline Trust Co Boosts Position in Mastercard Inc
Coastline Trust Co Boosts Position in Mastercard Inc
Walmart Inc  Shares Sold by DORCHESTER WEALTH MANAGEMENT Co
Walmart Inc Shares Sold by DORCHESTER WEALTH MANAGEMENT Co
1st Constitution Bancorp  Shares Sold by Deutsche Bank AG
1st Constitution Bancorp Shares Sold by Deutsche Bank AG


© 2006-2019 Ticker Report